Clinical Trials Browser

INDUSTRY × zolbetuximab × 1 year × Clear all

NCT06901531 2026-06-05

LUCERNA

Phase 3 Recruiting

Adenocarcinoma, Neoplasms

NCT03816163 2026-06-04

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07431281 2026-05-27

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT03504397 2026-05-04

Spotlight

Phase 3 Active not recruiting

565 enrolled 63 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03653507 2026-04-17

GLOW

Phase 3 Active not recruiting

507 enrolled 65 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03505320 2026-04-03

ILUSTRO

Phase 2 Active not recruiting

Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT06902545 2026-03-11

A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Adenocarcinoma, Neoplasms

NCT06396091 2025-11-13

A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer

Phase 1 Active not recruiting

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT06048081 2025-09-10

Early Access Program for Zolbetuximab

Adenocarcinoma

NCT01630083 2025-06-15

FAST

Phase 2 Completed

Gastrointestinal

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction